SABS
SAB Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.72
+0.00%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 1353.88x
Trailing multiples
Trailing twelve months
- P/E TTM
- 1.04x
- PEG TTM
- —
- Price / book
- 1.58x
- Price / sales
- —
- Price / cash flow
- -4.96x
Enterprise value
- Enterprise value
- $241.0M
- EV / sales
- —
- EV / EBITDA
- -25.47x
- EV / EBIT
- -3.35x
- Market cap
- $338.5M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026